


### Listing of Claims:

This listing of claims reflects all claim amendments and replaces all prior versions, and listings, of claims in the application. Material to be inserted is in **bold and underline**, and material to be deleted is in ~~strikeout~~ or (if the deletion is of five or fewer consecutive characters or would be difficult to see) in double brackets [[ ]].



Please cancel claims 7 and 9-13, without prejudice.

Please amend claims 1 and 3 as indicated below.

1. (Currently Amended) A method of treating a mammal in which migration of monocytes or T lymphocytes is increased, or production of IL-10 is increased, and inhibition of said increase is desired, comprising: administration of a compound represented by the following general formula (I) for inhibiting MCP-1 production:




wherein R<sup>1</sup> represents a hydrogen atom or a group of the following formula (II) or (III):



wherein the groups of formula (II) and formula (III) may also be their pharmaceutically acceptable salts;

R<sup>2</sup> represents COOH or a group of the following formula (IV):



or their pharmaceutically acceptable salts;

X represents C=O or CH; and,

dotted lines suitably represent a double bond;

provided that said compound represented by the formula (I) is not MUN-014 or  
glycyrrhizin (GR).

2. (Previously Presented) The method according to claim 1 wherein, the pharmaceutically acceptable salts in the above formulas (II), (III) and (IV) are sodium salts, potassium salts, ammonium salts or combinations thereof.

3. (Currently Amended) The method according to claim 8 wherein, a compound of the above general formula (I) is one of either:

olean-11,13(18)-diene-30-carboxy-3 $\beta$ -yl-(disodium 2-O- $\beta$ -

glucopyranuronosyl- $\beta$ -D-glucopyranuronate);

sodium olean-3 $\beta$ -hydroxy-11-oxo-12-ene-30-ate;

disodium olean-9(11),12-diene-3 $\beta$ ,30-diol-3 $\beta$ ,30-

O-dihemipthalate;

disodium olean-3 $\beta$ -hydroxy-11,13(18)-diene-30-ate-

3 $\beta$ -O-hemipthalate; or

disodium olean-3 $\beta$ -hydroxy-11-oxo-12-ene-30-ate-3 $\beta$ -O-

hemipthalate; ~~or~~

~~monoammonium 20 $\beta$ -carboxy-11-oxo-30-norolean-12-en-~~

~~3 $\beta$ -yl-2-O- $\beta$ -D-glucopyranuronosyl- $\beta$ -D-~~

~~glucopyranosidouronate.~~

4-7 (Canceled)

8. (Previously Presented) The method according to claim 2, wherein the pharmaceutically acceptable salts are sodium salts or ammonium salts.

9-13. (Canceled)